Good morning. Elizabeth Cooney here in STAT’s Boston HQ, collaborating with Ed Silverman in San Francisco, where he has joined STAT’s corps of reporters covering the J.P. Morgan Healthcare Conference (or, as Ed refers to it, the annual Woodstock gathering for biopharma types). Here’s what we’re watching today, starting with that meeting:

A year after STAT found more men named Michael than female CEOs giving corporate presentations at the J.P. Morgan Healthcare Conference, the tables have turned, STAT reports. At this week’s confab, there will be 33 female CEOs presenting corporate updates, compared to 19 men named Michael. And yet women will still be massively outnumbered on one of biotech’s biggest stages: Men represent 90 percent of the 553 executives who will give corporate presentations at JPM. That’s down from 94 percent last year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Talk about inflation … for drug prices?! Only in America would $8 Billion (with a ‘B’) describe the sale price for “a tiny company.” (Cf Lilly purchase of Loxo mentioned above)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy